Heron Therapeutics (NASDAQ: HRTX) reported Q2 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $36.02 million versus the consensus estimate of $36.09 million.

Guidance:

Adjusted Operating Expenses: $107.0 to $111.0 million
Adjusted EBITDA: $(10.0) to $3.0 million

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.